¼¼°èÀÇ ´ã³¶¾Ï Ä¡·á ½ÃÀå(2023-2030³â)
Global Gall Bladder Cancer Treatment Market - 2023-2030
»óǰÄÚµå : 1297794
¸®¼­Ä¡»ç : DataM Intelligence
¹ßÇàÀÏ : 2023³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 195 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,350 £Ü 6,294,000
PDF & Excel (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,850 £Ü 7,017,000
PDF & Excel (Multiple User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,850 £Ü 11,358,000
PDF & Excel (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

½ÃÀå °³¿ä

´ã³¶¾Ï Ä¡·á ½ÃÀå ±Ô¸ð´Â 2022³â 7,950¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2030³â¿¡´Â 1¾ï 2,140¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼°è ´ã³¶¾Ï Ä¡·á ½ÃÀåÀº ¿¹Ãø ±â°£ÀÎ 2023³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 5.5%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ã³¶¾Ï Ä¡·á ½ÃÀåÀº Àüü ¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ÇÑ ºÐ¾ß·Î ´ã³¶¾Ï Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ¼ö¼ú, È­Çпä¹ý, ¹æ»ç¼± ¿ä¹ý, Ç¥ÀûÄ¡·á, ¸é¿ª¿ä¹ý µî ´Ù¾çÇÑ Ä¡·á¹ýÀ» Æ÷ÇÔÇÕ´Ï´Ù.

ÀÌ ½ÃÀåÀº »õ·Î¿î Ä¡·á Á¢±Ù¹ý°ú Ä¡·á¹ý Çõ½ÅÀÌ µîÀåÇÔ¿¡ µû¶ó °è¼Ó ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ¿¬±¸, ÀÓ»ó ½ÃÇè, ÀÇ·á ¼­ºñ½º Á¦°øÀÚ, ¿¬±¸ÀÚ ¹× Á¦¾à ȸ»ç °£ÀÇ Çù·ÂÀÌ ½ÃÀåÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ã³¶¾Ï Ä¡·á ½ÃÀåÀº ´ã³¶¾Ï À¯º´·ü Áõ°¡, Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀÎ½Ä °³¼±, Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¿¬±¸ °³¹ß Áõ°¡, À¯¸®ÇÑ »óȯ Á¤Ã¥, °í±Þ Áø´Ü ½Ã¼³ µµÀÔ Áõ°¡, ±â¼ú ¹ßÀü µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

°í±Þ Áø´Ü ½Ã¼³ ä¿ë Áõ°¡

´ã³¶¾Ï Ä¡·á¿¡¼­ ÷´Ü Áø´Ü ½Ã¼³ÀÇ Ã¤Åà Áõ°¡´Â ½ÃÀå Á¡À¯À²À» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÷´Ü Áø´Ü ½Ã¼³Àº ´ã³¶¾ÏÀÇ Á¶±â ¹ß°ß, Á¤È®ÇÑ Áø´Ü ¹× º´±â °áÁ¤¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù.

¶ÇÇÑ, ºÐÀÚ °Ë»ç ¹× ¹ÙÀÌ¿À¸¶Ä¿ ºÐ¼®À» Æ÷ÇÔÇÑ Ã·´Ü Áø´Ü ±â¼úÀº ´ã³¶¾Ï Ä¡·á¿¡¼­ °³ÀÎ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ƯÁ¤ À¯ÀüÀÚ µ¹¿¬º¯ÀÌ, ¹ÙÀÌ¿À¸¶Ä¿ ¶Ç´Â Á¾¾çÀÇ ºÐÀÚÀû Ư¡À» ½Äº°ÇÏ¿© Ç¥Àû Ä¡·á ¹× ¸ÂÃãÇü Ä¡·á °èȹÀ» ¼ö¸³ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¿¹¸¦ µé¾î, ¼øÈ¯ miR-141Àº ´ã³¶¾ÏÀÇ Áø´Ü, ¿¹ÈÄ ¹× Ä¡·á Ç¥ÀûÀ» À§ÇÑ ÀáÀçÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿ÀÔ´Ï´Ù.

Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¿¬±¸ ¹× °³¹ßÀÇ Áõ°¡

´ã³¶¾Ï Ä¡·á¹ýÀ» ¹ßÀü½Ã۱â À§Çؼ­´Â ¿¬±¸ °³¹ß ³ë·ÂÀÌ ÇʼöÀûÀÔ´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ¿¬±¸ °³¹ßÀº ´ã³¶¾ÏÀÇ ±Ùº»ÀûÀÎ ¸ÞÄ¿´ÏÁòÀ» ÀÌÇØÇϰí, »õ·Î¿î Ä¡·á Ç¥ÀûÀ» ã¾Æ³»°í, Çõ½ÅÀûÀÎ Ä¡·á Á¢±Ù¹ýÀ» °³¹ßÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

Ç¥Àû Ä¡·áÀÇ ÃâÇöÀº ´ã³¶¾ÏÀ» Æ÷ÇÔÇÑ ¾Ï Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ƯÁ¤ ºÐÀÚ Ç¥ÀûÀ» ½Äº°Çϰí ÀÌ·¯ÇÑ Ç¥ÀûÀ» ¼±ÅÃÀûÀ¸·Î ¾ïÁ¦Çϰųª ÆÄ±«ÇÏ´Â ¾à¹°À» °³¹ßÇÏ¿© º¸´Ù È¿°úÀûÀÌ°í µ¶¼ºÀÌ ³·Àº Ä¡·á¹ýÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. Ç¥Àû Ä¡·á´Â ȯÀÚ °³°³ÀÎÀÇ ºÐÀÚÀû Ư¼º¿¡ ¸Â´Â °³ÀÎÈ­µÇ°í Á¤È®ÇÑ Ä¡·á ¿É¼ÇÀÇ °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù.

¿¹¸¦ µé¾î, 2023³â 3¿ù °ø¸³ ÀÇÇÐ ¿¬±¸ ´ëÇÐÀÎ PGIMER Chandigarh´Â ¸»±â ´ã³¶¾ÏÀÇ Ä¡·á¹ýÀ¸·Î ºñ°¡¿ªÀû Àü±âõ°ø¹ýÀÇ ÀÓ»ó½ÃÇèÀ» ½ÃÀÛÇß½À´Ï´Ù. ÀÌ ¹æ¹ýÀº ¾Ï Á¾¾ç¿¡ °íÀü¾ÐÀÇ ´Ü½Ã°£ Àü±â ÆÞ½º¸¦ ÁÖ¾î Á¾¾ç ¼¼Æ÷¸¦ ÆÄ±«ÇÏ¿© Ä¡À¯¸¦ °¡´ÉÇÏ°Ô ÇÏ´Â ¹æ¹ýÀÔ´Ï´Ù.

Á¦ÇÑµÈ Ä¡·á ¿É¼Ç

´Ù¸¥ ¾Ï¿¡ ºñÇØ ´ã³¶¾ÏÀº ƯÈ÷ ÁøÇ༺ ¹× ÀüÀ̼º ¾ÏÀÇ °æ¿ì Ä¡·á ¿É¼ÇÀÌ Á¦ÇÑÀûÀÔ´Ï´Ù. Á¦ÇÑµÈ Ä¡·á ¿É¼ÇÀº ÃÖÀûÀÇ Ä¡·á °á°ú¿Í ȯÀÚÀÇ ¹ÝÀÀ·ü ÀúÇÏ·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. ±âÁ¸ Ä¡·á¹ýÀÇ È¿°ú°¡ Á¦ÇÑÀûÀ̰ųª ȯÀÚ°¡ ³»¼ºÀ» º¸ÀÌ´Â °æ¿ì, ÀÇ·áÁøÀÌ ¼±ÅÃÇÒ ¼ö ÀÖ´Â ¿É¼ÇÀÌ Á¦ÇѵǾî ȯÀÚÀÇ Ä¡·á °á°ú¿Í ¸¸Á·µµ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

´ã³¶¾ÏÀº ´Ù¾çÇÑ ¾ÆÇü°ú ºÐÀÚÀû Ư¡À» °¡Áø º¹ÀâÇÑ ÁúȯÀÔ´Ï´Ù. ÇÑÁ¤µÈ Ä¡·á ¿É¼ÇÀ¸·Î´Â ÁúȯÀÇ ÀÌÁú¼º¿¡ ÃæºÐÈ÷ ´ëÀÀÇÏÁö ¸øÇÒ ¼ö ÀÖÀ¸¸ç, ȯÀÚº° ¸ÂÃãÈ­µÈ Á¤È®ÇÑ Ä¡·á Á¢±Ù¹ýÀ» Á¦°øÇÏ±â ¾î·Æ½À´Ï´Ù.

COVID-19 ¿µÇ⠺м®

COVID-19ÀÇ ´ëÀ¯ÇàÀº ´ã³¶¾Ï Ä¡·á ½ÃÀåÀ» Æ÷ÇÔÇÑ ÇコÄÉ¾î »ê¾÷¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀº COVID-19 ȯÀÚ¸¦ °ü¸®ÇÏ´À¶ó ¹Ù»Ú°Ô ¿òÁ÷À̰í ÀÖ½À´Ï´Ù. ´ã³¶¾Ï ¼ö¼úÀ» Æ÷ÇÔÇÑ ±ä±ÞÇÏÁö ¾ÊÀº ½Ã¼úÀº Á¾Á¾ ¿¬±âµÇ°Å³ª ÁߴܵǾî Ä¡·á°¡ Áö¿¬µÇ°Å³ª ÁߴܵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ´Â ´ã³¶¾Ï ȯÀÚÀÇ Àû½Ã Ä¡·á ½ÃÀÛ¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ COVID-19 °¨¿° À§ÇèÀ» ÃÖ¼ÒÈ­Çϰí ÀÇ·á ÀÚ¿øÀ» ÃÖÀûÈ­Çϱâ À§ÇØ Ä¡·á Á¢±Ù ¹æ½ÄÀ» º¯°æÇØ¾ß Çß½À´Ï´Ù. °æ¿ì¿¡ µû¶ó ¼ö¼úÀû Ä¡·á°¡ Àü½Å ¿ä¹ýÀ̳ª ¹æ»ç¼± Ä¡·á¿Í °°Àº ´ëü Ä¡·á¹ýÀ¸·Î ´ëüµÇ°Å³ª ¿¬±âµÇ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ´ã³¶¾Ï ȯÀÚÀÇ Àü¹ÝÀûÀÎ °ü¸®¿Í °á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

·¯½Ã¾Æ-¿ìÅ©¶óÀ̳ª ºÐÀï ºÐ¼®

·¯½Ã¾Æ¿Í ¿ìÅ©¶óÀ̳ªÀÇ ºÐÀïÀº ´ã³¶¾Ï Ä¡·á ½ÃÀå¿¡ Å« ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ºÐÀïÀº °ø±Þ¸Á¿¡ È¥¶õÀ» ¾ß±âÇϰí ÀǾàǰ, ¼ö¼ú Àåºñ, Áø´Ü µµ±¸ µî Çʼö ÀÇ·á¿ëǰÀÇ Á¢±ÙÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °ø±Þ ºÎÁ·°ú Á¢±Ù¼º Á¦ÇÑÀº ´ã³¶¾Ï ȯÀÚ¿¡°Ô Á¦°øµÇ´Â ÀÇ·á ¼­ºñ½ºÀÇ Áú¿¡ ¿µÇâÀ» ¹ÌÃÄ ÃÖÀûÀÇ Ä¡·á °á°ú¸¦ ¾òÁö ¸øÇÒ ¼ö ÀÖ½À´Ï´Ù.

ºÐÀï »óȲÀº ÀÇ·áÁøÀÇ ÀÌÁÖ¿Í ÀÌÁÖ·Î À̾îÁ® ÀÇ·á ½Ã½ºÅÛÀ» ´õ¿í ±äÀå½Ãų ¼ö ÀÖ½À´Ï´Ù. ¼÷·ÃµÈ ÀÇ·áÁøÀÇ ¼Õ½ÇÀº ´ã³¶¾Ï ȯÀÚ¿¡°Ô ÀûÀýÇϰí Àü¹®ÀûÀÎ Ä¡·á¸¦ Á¦°øÇÒ ¼ö ÀÖ´Â ´É·Â¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÇ·áÁøÀº ºÐÀï ±â°£ µ¿¾È ÀÇÇÐ ±³À° ¹× ÈÆ·Ã ±âȸ¸¦ ¾ò±â°¡ ¾î·Á¿öÁ® ÃֽŠÀÇ·á ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ´É·Â¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

Á¦5Àå ¾÷°è ºÐ¼®

Á¦6Àå COVID-19 ºÐ¼®

Á¦7Àå Ä¡·áº°

Á¦8Àå ÀûÀÀÁõº°

Á¦9Àå ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå Áö¿ªº°

Á¦11Àå °æÀï »óȲ

Á¦12Àå ±â¾÷ °³¿ä

Á¦13Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Market Overview

The Gall Bladder Cancer Treatment Market size reached US$ 79.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$121.4 million by 2030. The Global Gall Bladder Cancer Treatment Market is exhibiting at a CAGR of 5.5% during the forecast period 2023-2030.

The Gall Bladder Cancer Treatment Market is a segment of the overall oncology therapeutics market, focusing on treating gallbladder cancer. It involves various modalities such as surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.

The market continues to evolve as new treatment approaches and therapeutic innovations emerge. Ongoing research, clinical trials, and collaborations among healthcare providers, researchers, and pharmaceutical companies are expected to shape the market's future.

The gall bladder cancer treatment market is driven by factors such as the increasing prevalence of gall bladder cancer, increasing awareness of treatment options, increasing research and developments in treatment options, favorable reimbursement policies, increasing adoption of advanced diagnostic facilities, and technological advancements.

Market Dynamics

Increasing Adoption of Advanced Diagnostic Facilities

The increasing adoption of advanced diagnostic facilities for gall bladder cancer treatment is expected to drive the market share. Advanced diagnostic facilities play a crucial role in the early detection, accurate diagnosis, and staging of gallbladder cancer.

Furthermore, advanced diagnostic techniques, including molecular testing and biomarker analysis, contribute to personalized medicine approaches in gallbladder cancer treatment. These techniques help identify specific genetic mutations, biomarkers, or molecular characteristics of the tumor, enabling targeted therapies and tailored treatment plans. For instance, Circulating miR-141 as a potential biomarker for diagnosis, prognosis, and therapeutic targets in gallbladder cancer.

Increasing Research and Developments in Treatment Options

Research and development efforts are vital in advancing treatment options for gallbladder cancer. Ongoing research activities focus on understanding the underlying mechanisms of gallbladder cancer, identifying new therapeutic targets, and developing innovative treatment approaches.

The emergence of targeted therapies has revolutionized cancer treatment, including gallbladder cancer. Researchers are identifying specific molecular targets and developing drugs that selectively inhibit or disrupt these targets, leading to more effective and less toxic treatments. Targeted therapies offer the potential for personalized and precise treatment options tailored to individual patients' molecular characteristics.

For instance, in March 2023, PGIMER Chandigarh, a public postgraduate medical research university started trials of irreversible electroporation for the treatment of late-stage gallbladder cancer through the procedure, the cancer tumor is given short-term electric pulses with high voltage to break tumor cells; allowing healing.

Limited Treatment Options

Compared to other types of cancer, gallbladder cancer has limited treatment options, especially for advanced or metastatic cases. Limited treatment options may lead to suboptimal treatment outcomes and lower patient response rates. If existing treatments have limited efficacy or patients develop resistt can restrict the options available to healthcare providers, potentially impacting patient outcomes and satisfaction.

Gallbladder cancer is a complex disease with various subtypes and molecular characteristics. Limited treatment options may not adequately address the heterogeneity of the disease, making it challenging to provide personalized and precise treatment approaches for each patient.

COVID-19 Impact Analysis

The COVID-19 pandemic profoundly impacted the healthcare industry, including the gallbladder cancer treatment market. Healthcare systems around the world have been overwhelmed with the management of COVID-19 patients. Non-urgent procedures, including surgeries for gallbladder cancer, have been postponed or canceled in many cases, leading to treatment delays and interruptions. This has affected the timely initiation of treatment for patients with gallbladder cancer.

The pandemic has necessitated changes in treatment approaches to minimize the risk of COVID-19 transmission and optimize healthcare resources. In some cases, surgical interventions may have been replaced or delayed by alternative treatment modalities such as systemic or radiation therapy. These changes may impact the overall management and outcomes of gallbladder cancer patients.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict had a significant impact on the gallbladder cancer treatment market. The competition can disrupt supply chains and hinder the availability of essential medical supplies, including medications, surgical equipment, and diagnostic tools. Shortages or limited access to these supplies can impact the quality of care provided to gallbladder cancer patients, potentially leading to suboptimal treatment outcomes.

Conflict situations can lead to the migration or displacement of healthcare professionals, which can further strain the healthcare system. The loss of skilled medical personnel can impact the capacity to provide adequate and specialized care for gallbladder cancer patients. Additionally, healthcare workers may face challenges in accessing medical education and training opportunities during conflict, which can affect their ability to provide up-to-date care.

Segment Analysis

The Global Gall Bladder Cancer Treatment Market is segmented based on treatment, indication, end-user, and region.

Based on Treatment, the Chemotherapy Segment is Expected to Dominate the Market Share

The market for chemotherapy holds 38.2% of the global gallbladder cancer treatment market share in 2022. Chemotherapy plays an important role in treating gallbladder cancer, both as a primary treatment option and as part of a multimodal approach.

In cases of advanced or metastatic gallbladder cancer where curative surgical options are limited, chemotherapy serves as a palliative treatment to control symptoms, prolong survival, and enhance the quality of life for patients. Palliative chemotherapy can help shrink tumors, alleviate pain, and manage other cancer-related symptoms, offering relief to patients.

For instance, in May 2023, Genome & Company will revise its strategy in developing a biliary tract cancer treatment candidate, GEN-001. The company plans to confirm the treatment effect of its combined use with cytotoxic chemotherapies by reflecting on cancer's secondary treatment trend. The company had submitted applications for changing its investigational new drug (IND) plan for the domestic phase 2 clinical trial of GEN-001 to the Ministry of Food and Drug Safety.

Geographical Analysis

North America Holds the Largest Market Share Due to the High Disease Burden and Advanced Diagnostic Facilities

North America holds the 41.2% market share for the Gall Bladder Cancer Treatment Market in 2022 due to the high disease burden and advanced diagnostic facilities. North America has reported a relatively higher incidence of gallbladder cancer than other parts of the world. Factors such as lifestyle, obesity rates, and genetic predisposition may contribute to the higher disease burden in this region. The larger patient population translates to a greater demand for gallbladder cancer treatment, leading to a larger market share.

North America is known for its advanced healthcare infrastructure and diagnostic capabilities. The region has well-established medical facilities, including hospitals, clinics, and imaging centers, equipped with state-of-the-art technologies for early detection and accurate diagnosis of gallbladder cancer. This early detection facilitates the timely initiation of treatment and improves patient outcomes.

Competitive Landscape

The major global players in the market include: Eli Lilly and Company, Bristol-Myers Squibb Company, Cipla Inc, Pfizer Inc, F. Hoffmann-La Roche Ltd, Sanofi Inc, OncoTherapy Science Inc, Intuitive Surgical Inc, GLS Pharma Ltd, and Sun Pharmaceutical Industries Ltd.

Why Purchase the Report?

The Global Gall Bladder Cancer Treatment Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 Pages.

Target Audience 2023

Table of Contents

1. Methodology and Scope

2. Definition and Overview

3. Executive Summary

4. Dynamics

5. Industry Analysis

6. COVID-19 Analysis

7. By Treatment

8. By Indication

9. By End-User

10. By Region

11. Competitive Landscape

12. Company Profiles

LIST NOT EXHAUSTIVE

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â